Lotus Pharmaceuticals IncOTC Pink - Limited Information:LTUS
- LAST PRICE0.0050
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0050
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lotus Pharmaceuticals Inc | 13.5M | 0.1x | +42.39% |
Cumberland Pharmaceuticals Inc | 23.2M | -3.6x | --- |
Aoxing Pharmaceutical Company Inc | 1.7M | -0.3x | --- |
Tibet Pharmaceuticals Inc | 10.0 | 0.0x | --- |
Aida Pharmaceuticals Inc | 5.4K | 0.0x | --- |
Clever Leaves Holdings Inc | 6.8M | -0.3x | --- |
Company Information
Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.
Contact Information
- Headquarters
- 16 Cheng Zhuang Road, Feng Tai DistrictBEIJING, BEJ, China 100071
- Phone
- 106-389-9868
- Fax
- 106-389-9867
Executives
- Chairman of the Board, President, Chief Executive Officer
- Zhongyi Liu
- Chief Financial Officer
- Yan Zeng
- Vice President - Corporate Development
- Xing Shen
- Director
- Lu Jun
- Independent Director
- Fan Lijun
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.5M |
|---|---|
Revenue (TTM) | $70.8M |
Shares Outstanding | 2.7B |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.36 |
EPS | $0.06 |
Book Value | $3.33 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | 3.5x |
Operating Margin | 1.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
